FDA approves first test of CRISPR to correct genetic defect causing sickle cell disease
April 01, 2021
CRISPR-Cas9 treatment of sickle cell disease has been approved for clinical trials by the U.S. Food and Drug Administration. Researchers will now test CRISPR-Cas9 on humans to directly correct the mutation in the beta-globin gene responsible for sickle cell disease.